Wednesday, May 20, 2015

Image: 3Dme Creative Studio / Shutterstock.com

Potential new vaccine blocks every strain of HIV

A new drug candidate is so potent against all strains of HIV, researchers think it could work as a new kind of vaccine.

Developed by researchers from more than a dozen research institutions and led by a team at the Scripps Research Institute in the US, the drug is effective against doses of HIV-1, HIV-2 and SIV (simian immunodeficiency virus) that have been extracted from humans or rhesus macaques - including what researchers consider to be the ‘hardest-to-stop’ variants. It worked against doses of HIV that are way higher than what would be transmitted between humans, and works for at least eight months after injection.

"Our compound is the broadest and most potent entry inhibitor described so far,” lead researcher Michael Farzan from the Scripps Institute said in a press release. "Unlike antibodies, which fail to neutralise a large fraction of HIV-1 strains, our protein has been effective against all strains tested, raising the possibility it could offer an effective HIV vaccine alternative.”

While traditional vaccines work by delivering a tiny, weakened dose of a virus to train your immune system to thwart an actual attack, this drug does something quite different. The way HIV infects a person is by targeting their T lymphocytes - a very specialised type of white blood cell - and injecting its own genetic material inside to transform them into HIV-producing machines. So, quite literally, it turns our immune systems against us. 

But what Farzan’s team has discovered is that a particular type of protein found on the surface of white blood cells can actually bind to the surface of the HIV virus in two different places simultaneously, which means that not only does the virus no longer have a chance to change the position of its receptors to escape, it’s also being blocked from entering the T lymphocyte cells.

"When antibodies try to mimic the receptor, they touch a lot of other parts of the viral envelope that HIV can change with ease,"said one of the team, Matthew Gardner, from the Scripps Institute. "We've developed a direct mimic of the receptors without providing many avenues that the virus can use to escape, so we catch every virus thus far.”

According to James Gallagher at BBC News, the vaccine would be delivered via a weak, harmless type of virus that would introduce a section of DNA to a patient’s healthy muscle cells, containing instructions for how to produce this HIV-blocking protein. The protein would then be pumped out into the bloodstream over and over, protecting the patient from being infected over several months. The team reported inNature that the effects of the drug lasted for at least 34 weeks in their monkey subjects, but they think they could get it to last for years, perhaps even decades.

"We are closer than any other approach to universal protection, but we still have hurdles, primarily with safety for giving it to many, many people,” Franzen told the BBC. One such concern is that no one really knows what the long-term implications would be for a person who is having an anti-HIV response being pumped around their body non-stop. The team will be looking into this when they get their human trials underway.

"In the absence of a vaccine that can elicit broadly protective immunity and prevent infection, and given the lack of major breakthroughs on the horizon to provide one, the idea of conferring potent, sustained vaccine-like protection against HIV infection through gene therapy is certainly worth strong consideration,” Nancy Haigwood from the Oregon Health & Science University in the US, who wasn’t involved in the study, told the BBC

Source: BBC News

New Vaccine For HIV

Tuesday, May 19, 2015

T-Mobile leak reveals free smartphone offer for prepaid accounts


The idea of getting a free smartphone with service is nothing new; for years, the US market has been dominated by subsidized phone sales, and so long as you didn’t demand the latest and greatest flagships, you could always find a good number of free-on-contract options. In recent years, though, there’s been a shakeup in favor of installment plans, not to mention a rise in popularity of prepaid options, pushing the idea of free phones to the back burner. But today we learn of an upcoming deal for T-Mobile that puts the spotlight back on free phones in an unexpected way, revealing plans to give away a brand new smartphone to users with prepaid service.

We’ve already seen evidence of T-Mobile welcoming a couple new LG Androids to its lineup, the LG G Stylo and LG Leon. Now a leaked doc spells out the carrier’s plan to usher in the arrival of the LG Leon on May 20 with a free giveaway.

Subscribers on either Simple Choice No Credit plans or prepaid plans costing at least $40 a month will be able to get the LG Leon for free, according to this leak. The details differ a little – with prepaid users getting the phone for free straight away with their next $40 or better payment, and SCNC users paying a $150 deposit before getting the full cost of the phone back as a rebate after a month of service – but in either case, it works out to a free phone.

The LG Leon has a 4.5-inch FWVGA screen and runs a Snapdragon 400 SoC – not state-of-the-art by any stretch of the imagination, but free is free, right? And with word that this deal applies equally to new customers as well as existing ones, it’s hard to pass up, even if that means just keeping the Leon as a backup phone.

Source: TmoNews

FREE SMART PHONES FROM T-MOBILES

Apple acquires high-accuracy GPS firm Coherent Navigation

 theleetgeeks, via Flickr

Apple Maps might be tracking you more closely soon. The Cupertino, Calif., company has acquired Coherent Navigation, a developer of highly accurate GPS services, according to reports that surfaced over the weekend.

Coherent Navigation’s biggest technology combines standard GPS satellite information with data from low-Earth satellites owned by Iridium, a voice and data provider. While consumer GPS can be accurate to within three to five feet, Coherent’s High Integrity GPS can be accurate to a few centimeters.

MacRumors first reported that a few of the Bay Area startup’s employees, including CEO John Lego, have been working at Apple since the beginning of the year. Their website, which previously boasted about relationships with Boeing and the Department of Defense, has been taken down.

While this technology would be great for knowing which side of the street you’re on (maybe for transit directions?), high-accuracy GPS could also be a boon for autonomous cars. That would fit well withApple’s reported plans to challenge Google andTesla in autonomous driving. According to the New York Times, it wouldn’t be the first time Coherent’s technology was used for autonomous navigation.

However, many of Coherent’s past employees who are now at at Apple are working in location engineering or with the Maps team, according to LinkedIn profiles.

Apple acquires Coherent Navigation For accurate GPS

Monday, May 18, 2015


Huawei’s Nexus To Come With Kirin 930 And Metal Body

Google’s been rumored to be looking towards new manufacturers for this year’s Nexus. According to several speculations so far, the manufacturer of choice for the tech giant has been Huawei. But we’ve also heard about some news about LG considering to make the next Nexus. So while the current contender for Google’s Nexus throne this year is Huawei, its still too early to count other manufacturers out the race either. Nevertheless, we’ve manged to get some more information about the next Nexus.


Huawei’s Nexus Might Come With The Kirin 930 And 5.7 inch Display

While LG’s seemingly confirmed that its considering on manufacturing the next Nexus, the rumor mill is active on pumping more and new information about Huawei’s alleged Nexus. According to information so far, the device might be choosing to stick with the Snapdragon 810 as of now. This most likely means that overheating issues can be expected on the device and right on cue, new information suggests that Huawei might be choosing to employ its own Kirin 930 on the Nexus. The Kirin 930 is Huawei’s in house processor which can be expected to give several chipsets a run for their money.

But while the Kirin 930 might sound like a plausible option for the Nexus, Huawei might be better suited to choose the Kirin 940 or the 950 both of which feature Cortex A72 designs, meaning that you won’t have to worry about high performance on the Nexus. We also get to know more about the display size, design and screen resolution for the device. Allegedly, the next Nexus can be expected to come with a 5.7 inch display, with the device expected to be similar to Huawei’s Mate 8 expected later this year and feature a complete premium metal build. Screen resolution for the device is expected to be 2560 x 1440. That’s all that we have for you today. Stay tuned and let us know what you think in the comments section.

Kirin 930 And Metal Body -Huawei's Nexus

AOL will become a subsidiary of Verizon

Verizon Buys AOL


So this just happened. AOL, owner of TechCrunch, is getting acquired: U.S. carrier Verizonsaid in a statement that it is buying the company for $4.4 billion, or $50 per share. We’ve just been sent an internal memo about the deal that we are embedding below.

A bigger push into content and mobile videos

AOL will become a subsidiary of Verizon as part of the deal, overseeing a bigger push into content and mobile video by Verizon.

“Verizon’s acquisition further drives its LTE wireless video and OTT (over-the-top video) strategy,” the carrier said in a statement.

In addition to original content across different platforms like video and written word, and desktop and mobile, there are other assets that could be interesting fits for Verizon.

For starters, AOL has been building up a programmatic advertising business to build up how AOL monetizes alongside newer formats like video and mobile. Currently that business — which is the fastest growing operation at AOL in terms of revenues — is split between ads on AOL-owned sites and third-party sites. Verizon picking this up could potentially further build out both, with the company partnering with the likes of ESPN to develop content and also giving the AOL-owned properties potentially much bigger audiences.

The other area of AOL’s business that is a fit for Verizon is the company’s still-lingering dial-up business, which is remains a big revenue generator for AOL, last quarter pulling in $182.6 million.

That may be a decline of 7 percent compared to a year ago but, as a business that gets almost no investment but continues to run, membership (where the dial-up business sits) is still a majority of the company’s operating income. Verizon could potentially tap these customers for potential switch to broadband and other services on top of that, an area where AOL hasn’t really innovated on its own.

If you recall there were rumors earlier this year that Verizon was eyeing up the company. While Verizon appeared to dismiss the reports at the time, it turns out that it was definitely interested after all.


For what it’s worth, we’d heard the same about Verizon being interested but that there were some sticking points about whether it would buy only a part or all of AOL, which appear to have been put to one side for now.

“The deal means we will be a division of Verizon and we will oversee AOL’s current assets plus additional assets from Verizon that are targeted at the mobile and video media space. The deal will not change our strategy – it will expand it greatly. The deal will give our content businesses more distribution and it will give our advertisers more distribution and mobile-first features. The deal will add scale and it will add a mobile lens to everything we do inside of our content, video, and ads strategy,” Tim Armstrong, AOL’s chairman and CEO, said in the memo.

There are lingering questions about whether it’s an all-in deal for the longer term, or whether certain operations that are not as central to Verizon’s bigger strategy may eventually get offloaded.

AOL will be having an all-hands at 10am Eastern time this morning and we’ll report what comes up there, too.

Armstrong will continue to head up AOL after the deal is completed.


Full memo below, and more to come.

AOLers –
As you have heard me say many times over the last 5 years since we became an independent AOL, we are building toward becoming the largest media technology company in the world. While there are search platforms, social platforms, and commerce platforms, we have built a very meaningful media platform and AOL today is a media platform company powering our brands and the brands of over 30,000 partners.
If there is one key to our journey to building the largest digital media platform in the world, it is mobile. Mobile will represent 80% of consumers’ media consumption in the coming years and if we are going to lead, we need to lead in mobile. Over the last 18 months we set a goal of moving AOL into a leading position in mobile, mobile video, and mobile registered consumers. We are approaching 400 million global consumers, we have built one of the best advertising platforms in the world, and we have one of the most talented teams in the world – and now it is time for us to fully open up the mobile frontier.
Today, we are announcing that the largest and most innovative wireless and cable company – and the one investing the most in high quality mobile content – is acquiring AOL with the strategy of building the biggest media platform in the world. The company is Verizon and the deal will game-change the size and scale of AOL’s opportunity. Just as AOL has propelled The Huffington Post, Adap.tv, TechCrunch, and other companies we have acquired, Verizon will propel AOL and comes to the table with over 100 million mobile consumers, content deals with the likes of the NFL, and a meaningful strategy in mobile video.
The decision to enter into an agreement with Verizon was made over a long and thoughtful time period and both companies see significant opportunity to service consumers and customers in a differentiated and exciting way. On a personal level, the decision to go forward with an agreement was predicated on giving our talent the best opportunity to build a multi-decade business that would be deeply growth oriented and aimed directly at the platform shift that video and mobile are offering the world – today and 20 years from now.
There are two important questions you might have at this point in the letter:
1. What does this mean?
2. What does this mean for me (meaning you)?
The deal means we will be a division of Verizon and we will oversee AOL’s current assets plus additional assets from Verizon that are targeted at the mobile and video media space. The deal will not change our strategy – it will expand it greatly. The deal will give our content businesses more distribution and it will give our advertisers more distribution and mobile-first features. The deal will add scale and it will add a mobile lens to everything we do inside of our content, video, and ads strategy.
For you this means growth, it means mobile, and it means compensation that will be equal or better to your AOL compensation. Your benefits will not change in 2015. We will eventually go on Verizon’s benefit plan, but that won’t happen until 2016 or later and we will work with Verizon to make sure the benefits are strong and cover important areas of people’s lives. Your job and what you do on a daily basis should be enhanced by the market opportunity this deal is targeted to capture. The simple answer to the question of “what does this mean for you?” should be, “I just got more resources, more support and more growth opportunity.”
The leadership at AOL is staying and I am staying – enthusiastically, and we made that part of the deal. We have the opportunity to build a unique and globally scaled media technology company with the scale and resources we need to make that happen. Verizon and AOL are very large partners today – in content, in ads, and in the technology. We know their team well and they know our team well. The cultures share very similar values and are both working on very similar ways to do good while doing well. Diversity and women’s leadership are at the top of both companies’ agendas and we look forward to having a consumer and industry impact on those important issues.
The future in front of AOL and the industry requires scale, mobile, and video – and partnerships. In our lifetime, we will see the connection of the world on very large and very fast networks – and to play in that world with our strategy requires us to take the natural steps to secure our ability to shoot for the stars. This deal is aimed at the stars and we are going to pursue the joint vision of building the most significant media platform in the world.
I have been a buyer of AOL over the last 5 years – and that is an investment in one thing – our talent. We have reviewed every hire coming into the company over the last 5 years and we have taken extraordinary risks and faced extraordinary challenges over the last 5 years. There is nothing more meaningful than watching our team turn-around this great company and restoring it to growth when most people had left it for dead.
AOL is back and now we are joining forces with Verizon to build the best media technology company in the world. Let’s mobilize. – TA @
http://techcrunch.com/

Verizon Buys AOL ,The Internal memo says

Thursday, May 14, 2015

Brain Eating Amoeba (Naegleria fowleri)-Kills you by turning your body against you !!



"Naegleria fowleri -brain eating amoeba-is a free-living, thermophilic excavate form of protist typically found in warm bodies of fresh water, such as ponds, lakes, rivers, and hot springs"



If someone swims in one of these infested pools and gets water up their nose, the amoeba heads for the brain in search of a meal. Once there, it starts to destroy tissue by ingesting cells and releasing proteins that make other cells disintegrate.

The immune system launches a counter-attack by flooding the brain with immune cells, causing inflammation and swelling. It seldom works: of the 132 people known to have been infected in the US since 1962, only three survived.

The problem is that enzymes released by the immune cells can also end up destroying brain tissue. And the swelling triggered by the immune system eventually squashes the brainstem, fatally shutting off communication between the body and the brain.

What Is a Brain-Eating Amoeba?


Amoebas are single-celled organisms. The so-called brain-eating amoeba is a species discovered in 1965. It's formal name is Naegleria fowleri. Although first identified in Australia, this amoeba is believed to have evolved in the U.S.

There are several species of Naegleria but only the fowleri species causes human disease. There are several fowleri subtypes. All are believed equally dangerous.

N. fowleri is microscopic: 8 micrometers to 15 micrometers in size, depending on its life stage and environment. By comparison, a hair is 40 to 50 micrometers wide.

Like other amoebas, Naegleria reproduces by cell division. When conditions aren't right, the amoebas become inactive cysts. When conditions are favorable, the cysts turn into trophozoites -- the feeding form of the amoeba.


Where Are Brain-Eating Amoebas Found?


Naegleria loves very warm water. It can survive in water as hot as 113 degrees Fahrenheit.

These amoebas can be found in warm places around the globe. N. fowleri is found in:
  • Warm lakes, ponds, and rock pits
  • Mud puddles
  • Warm, slow-flowing rivers, especially those with low water levels
  • Untreated swimming pools and spas
  • Untreated well water or untreated municipal water
  • Hot springs and other geothermal water sources
  • Thermally polluted water, such as runoff from power plants
  • Aquariums
  • Soil, including indoor dust

Naegleria can't live in salt water. It can't survive in properly treated swimming pools or in properly treated municipal water.

Most cases of N. fowleri disease occur in Southern or Southwestern states. Over half of all infections have been in Florida and Texas.

Primary amoebic meningoencephalitis cases, 1962 to 2012


How Do Amoebas Get in the Brain?


Studies suggest that N. fowleri amoebas are attracted to the chemicals that nerve cells use to communicate with one another. Once in the nose, the amoebas travel through the olfactory nerve (the nerve connected with sense of smell) into the frontal lobe of the brain.

Photo credit :CDC/Alexander J. da Silva

How to protect  from Brain eating Amoeba


Infections most often occur in July, August and September when temperatures are high for prolonged periods. Naegleria fowleri amoeba can be found in the following places:



• Warm fresh water such as lakes and rivers



• Geothermal water such as hot springs and drinking water sources



• Warm water discharge from industrial plants



To lower your risk, hold your nose shut, use nose clips or keep your head above water when playing in bodies of warm fresh water.



IIt makes sense to avoid swimming underwater, diving, water skiing, and jumping in warm, still waters during the late summer. It also makes sense to wear a nose clip when swimming, boating, or playing in or on warm waters.



It's also a good idea to avoid stirring up mud while taking part in such activities.



And if you are cleansing your nostrils, be sure to fill your neti pot or squeeze bottle with distilled or sterile water -- not tap water. You can also use water that has been boiled for one minute (three minutes at high elevations) and then cooled. And you can filter the water using filters with pores no larger than 1 micron (1 micrometer).

Brain Eating Amoeba Turns your body against you

Artificial Light Associated with Obesity, Study Says

Carbs, genetics, “bad” fats — there are many theories about the causes of obesity and associated illnesses like diabetes and heart disease.
But new research in today’s Proceedings of the National Academy of Sciences concludes obesity is not just about food.
Sander Kooijman and colleagues at the Leiden University Medical Center in the Netherlands say that weight gain may be increasingly common in today’s fast-paced global economy because prolonged artificial light exposure actually inhibits the fat-burning processes that normally occur during darkness.
“The modern 24-hour economy necessitates work at night and shifts social activities to the dark hours,” study co-author Patrick C. N. Rensen explained. “Our observations may implicate, assuming the data could be extrapolated to humans, that the current obesity epidemic is at least partly due to increased light pollution.”
Several years of research correlates weight gain with artificial light exposure, which is defined as any light that isn’t from the sun, including overhead lighting, computer screens, and streetlights. A 2013 article in the Federation of American Societies for Experimental Biology journal found that mice fed a low-fat diet but exposed to artificial light for prolonged periods of time actually gained more weight than mice fed a diet high in fat.

Why Would Light Make Us Fat?

Kooijman’s team wanted to know more about what exactly caused the correlation, so they looked at the exact mechanism behind that weight gain — specifically a type of fat known as brown adipose tissue (BAT). This tissue plays a central role in energy expenditure by changing energy from food into heat. In short, it burns calories.
Researchers exposed mice to artificial light for 12, 16, or 24 hours per day for five weeks. Mice exposed to artificial light for 24 hours, compared with 12 hours, had significantly higher fat composition despite consuming the same diet.
Further investigation revealed that BAT activity was decreased by light exposure. As mice were exposed to longer periods of light, conversion of fatty acids and glucose into heat was reduced. The longer the light shined, the fewer calories the mice burned.
In a culture where sunny days evoke swimsuits and beach bodies, it’s hard to understand why light exposure would lend itself to the deposition of fat. But the body’s circadian rhythms are uniquely attuned to variations in light and dark. Disruption of these basic physiological processes can have significant metabolic repercussions.
Researchers think that exposure to artificial light is actually tricking an evolutionary adaptation that encouraged our ancestors to store fat in the summer months to prepare for the colder, darker winter months.
“The so-called ‘day length’ prepares the body for cold adaptation due to seasonal variation,” said Rensen.
Shortened days, he explains, usually increase BAT activation to create heat in the body to prepare for cold, whereas longer days don’t require the creation of heat — so the body stores the excess energy, or fat, until it is needed.
“Lowering BAT activity in warm seasons may indeed result in beneficial storage of fat,” Rensen said.
But artificial light confuses the body. A night shift worker in a hospital, for example, might spend 12 hours under fluorescent lights and then several daylight hours running errands. If this happens multiple times a week, the body might adapt to the prolonged light exposure by reducing its normal fat-burning rate.

I Work Nights. Can I Get a Pill for That?

While research on artificial light exposure isn’t limited to mice, medications and therapies aimed at correcting faulty fat storage are still a long way off.
Rensen, Kooijman, and other researchers are looking at ways to increase BAT activity in mice and humans by developing drugs that act on the body’s “central biological clock,” an area of the brain known as the suprachiasmatic nuclei.
Until those magic pills allow us to travel across time zones jet-lag free or put in 24-hour workdays, the best advice science can offer is to try to sleep when it’s dark outside — or at least simulate darkness if you have a job that requires nighttime work.
“Restricting work and activities to daytime and sleeping in a dark bedroom may help prevent weight gain,” Rensen said.
For those who can’t limit their work to daylight hours and struggle with getting adequate sleep, a web search of “sleep hygiene” yields countless resources from sleep disorder centers across the United States.
UCLA’s Sleep Center has specific resources on sleep hygiene for shift workers. Sleep researchers have correlated poor sleep with increased risk of stroke, heart disease, and obesity.
One of the key recommendations of sleep experts? Limit artificial light exposure.

Obesity linked to exposure to Artificial light

Wednesday, May 13, 2015

Cuba Has a Lung Cancer Vaccine—America Wants It

Cuba has for several years had a promising therapeutic vaccine against lung cancer. The 55-year trade embargo led by the US made sure that Cuba was mostly where it stayed. Until—maybe—now.
The Obama administration has, of course, been trying to normalize relations with the island nation. And last month, during New York Gov. Andrew Cuomo’s visit to Havana, Roswell Park Cancer Institute finalized an agreement with Cuba’s Center for Molecular Immunology to develop a lung cancer vaccine and begin clinical trials in the US. Essentially, US researchers will bring the Cimavax vaccine stateside and get on track for approval by the Food and Drug Administration.
“The chance to evaluate a vaccine like this is a very exciting prospect,” says Candace Johnson, CEO of Roswell Park. She’s excited, most likely, because research on the vaccine so far shows that it has low toxicity, and it’s relatively cheap to produce and store. The Center for Molecular Immunology will give Roswell Park all of the documentation (how it’s produced, toxicity data, results from past trials) for an FDA drug application; Johnson says she hopes to get approval for testing Cimavax within six to eight months, and to start clinical trials in a year.
How did Cuba end up with a cutting edge immuno-oncology drug? Though the country is justly famous for cigars, rum, and baseball, it also has some of the best and most inventive biotech and medical research in the world. That’s especially notable for a country where the average worker earns $20 a month. Cuba spends a fraction of the money the US does on healthcare per individual; yet the average Cuban has a life expectancy on par with the average American. “They’ve had to do more with less,” says Johnson, “so they’ve had to be even more innovative with how they approach things. For over 40 years, they have had a preeminent immunology community.”
Despite decades of economic sanctions, Fidel and Raul Castro made biotechnology and medical research, particularly preventative medicine, a priority. After the 1981 dengue fever outbreak struck nearly 350,000 Cubans, the government established the Biological Front, an effort to focus research efforts by various agencies toward specific goals. Its first major accomplishment was the successful (and unexpected) production of interferon, a protein that plays a role in human immune response. Since then, Cuban immunologists made several other vaccination breakthroughs, including their own vaccines for meningitis B and hepatitis B, and monoclonal antibodies for kidney transplants.
The thing about making such great cigars is, smoking is really, really bad for you. Lung cancer is the fourth-leading cause of the death in Cuba. Medical researchers at the Center for Molecular Immunology worked on Cimavax for 25 years before the Ministry of Health made it available to the public—for free—in 2011. Each shot costs the government about $1. A Phase II trial from 2008 showed lung cancer patients who received the vaccine lived an average of four to six months longer than those who didn’t. That prompted Japan and some European countries to initiate Cimavax clinical trials as well.
To be fair, Cimavax probably won’t be a game-changing cancer drug in its current form. The vaccine doesn’t attack tumors directly, instead going after a protein that tumors produce which then circulates in the blood. That action spurs a person’s body to release antibodies against a hormone called epidermal growth factor, which typically spurs cell growth but can also, if unchecked, cause cancer. (Although most people normally think of a vaccine as something that prevents a disease, technically a vaccine is a substance that stimulates the immune system in some way.) So the point of Cimavax is to keep lung tumors from growing and metastasizing, turning a late-stage growth into something chronic but manageable.
But in the US and Europe, people with lung cancer already have treatment options with the same goal. Roswell Park researchers say they plan to explore the vaccine’s potential as a preventative intervention—making it more like a traditional vaccine. Furthermore, epidermal growth factor plays an important role in many other cancers, like prostate, breast, colon, and pancreatic cancer. “All those things are potential targets for this vaccine,” says Kelvin Lee, an immunologist at the company. Mostly for financial reasons, Cubans didn’t test Cimavax that way at all.
And that drug isn’t the only one with potential in the Cuban pharmacopeia. Thomas Rothstein, a biologist at the Feinstein Institute for Medical Research, has for six years worked with the Center for Molecular Immunology on another vaccine to treat lung cancer called Racotumomab, with an entirely different mechanism. (It messes with a particular lipid found in tumor cell membranes.) “Investigators from around the world are trying to crack the nut of cancer,” Rothstein says. “The Cubans are thinking in ways that are novel and clever.”
Although President Obama has used his executive power to lift some restrictions against medical and research equipment, Congress must lift the Cuban embargo before collaborative research can ramp up. Johnson hopes to see Cuba embrace more entrepreneurialism in science, and see the US soak up more creative approaches to medical research. Constrained by politics, the Cuban researchers had to innovate in ways the US and Europe did not. Now maybe they’ll be able to teach their colleagues what they learned.

Vaccine for Lung Cancer

Tuesday, May 12, 2015

Micro SD Card Slot for Mobile ! Do you Really Need Them ?



Expandable storage on mobile phones

For a long time now, they’ve been a subject with staunch movements both for and against it. The recent removal of a microSD card slot on the Samsung Galaxy S6, as well as Xiaomi’s Hugo Barra’s statement explaining why there isn’t any expandable storage option on the new Mi 4i sparked another round of heated discussion among smartphone users.

So why do smartphone users want microSD card slots, and why are smartphone makers shying away from them? Let’s break it down.

FOR…


(Image: ZDNet)

If there’s one reason why consumers want expandable storage on their smartphones, it’s this: cost. MicroSD cards have been around since the days of feature phones, offering a cheaper alternative to store pictures, ringtones and yes, even contacts when your SIM card runs out of space. Remember those days?

Back then, offering smaller storage space with a microSD card slot means the retail price of the device is lower, too, as it pushes the cost of manufacturing down. Users can then choose to buy a microSD card of varying sizes based on their needs.

These days, with expandable storage cards getting ever cheaper, you can add significant amounts of storage to a smartphone for anywhere between RM15 to several hundred ringgit, depending on the storage size and class. Imagine, for about RM60 to RM70 you can double the storage of a 32GB smartphone. In contrast, Apple charges you RM424 more for a 64GB iPhone 6 compared to a 32GB one. Of course, there are technical differences between natively offering extra storage and expanding them via microSD, but try explaining that to the average consumer.


Take that, evil conglomerate. (Image: ephotozine.com)

It doesn’t help either that a lot of smartphones today only pack 8GB of internal storage, prompting the need for expandable storage. It is especially prevalent in lower-end smartphones – with only 8GB of storage, the actual usage storage amounts to only 4GB or less, as there are system files that also take up storage space.

A microSD card slot allows smartphones to store videos on top of pictures, songs and other files that can be downloaded or transferred to a smart device. This allows consumers to turn their smartphones into portable entertainment devices to kill time, adding convenience to an already important personal device. If a smartphone only comes with 8 or 16GB of internal storage, no problem – just get a 32GB or indulge in one of those 200GB ones that were just announced earlier this year.



Another plus point in favour of having microSD card slots is portability. With so many cloud syncing options these days, one might suggest that having a physical copy of your data is still useful, especially in areas where Internet penetration is low, or in countries where Internet data is expensive. In these places, it is far cheaper to just slot in a microSD card to store internal data; switching between devices is relatively painless too, as it just requires the user to remove the card from the old phone and into the new one.

AGAINST…



(Image: shopclues.com)

Just like the above, there’s a simple reason why smartphone makers are moving away from adding microSD card support: performance.

A slower-class card, like Class 4, will have slower read/write speeds compared to a newer Class 10 microSD card, which is also more expensive. Hence, unknowing consumers would be more likely to purchase a slower memory card without understanding the consequences of using one. It’s similar to USB 2.0 and USB 3.0 – the difference is telling, especially when microSD cards can also be used on Android devices to store apps.

And why does this matter to the smartphone maker? Let Xiaomi’s Hugo Barra explain:


You think you’re buying like a Kingston or a SanDisk but you’re actually not, and they’re extremely poor quality, they’re slow, they sometimes just stop working, and it gives people huge number of issues, apps crashing all the time, users losing data, a lot of basically complaints and customer frustration. It’s gonna be a while before you finally accept that maybe the reason why it’s not performing is because you put in an SD card, right? You’re gonna blame the phone, you’re gonna blame the manufacturer, you’re gonna shout and scream and try to get it fixed, so many different ways until you say, ‘Actually, let me just take the SD card out and see what happens.’



In other words, which company wants that kind of bad press?



On the other hand, there’s the matter of performance itself. Samsung’s Galaxy S6, for example, is fitted with a new UFS 2.0 flash memorythat’s said to be significantly faster than standard flash memory on smartphones, and closer in performance to solid-state drives (SSDs). With that levels of read/write speeds, even a Class 10 memory card would appear slow – and that of course, would lead to complaints about the device “slowing down” in future. Hence, it meant that Samsung had to remove one of its most practical features for the sake of maintaining the S6’s premium performance.

It is this same reason that Hugo Barra argues against the addition of a microSD card slot on its affordable Mi 4i smartphone. “For high performance devices, we are fundamentally against an SD card slot,” he said.



Finally, in the same vein as “portability” in the earlier segment, smartphone makers would argue that with so many cloud syncing options, there’s no need for a microSD card slot on a smartphone. These days, a smartphone can have automatic camera backups using Google Drive, Dropbox, Microsoft OneDrive, Box and many more. Android also automatically syncs app data to your Google account, so each time you use a new device, your apps would be downloaded immediately. Why worry about a flimsy and tiny card when you have the power of the cloud?

MOVING FORWARD…

(Image: noelmace.com)

This would also surprise some of you, but Google has also been against cheap memory expansion years before anyone made a big deal out of it. This report way back in 2011 details how Google began encouraging other phone makers to increase internal storage on their smartphones, and reduce dependency on expandable memory. Bits of Barra’s argument above echoes in the report, stating the failure rates of SD cards were a big reason to avoid supporting expandable memory altogether.

The feature that allows apps to be transferred to a memory card, called Apps2SD and introduced in Android 2.2 Froyo, was meant to be a stop-gap solution. However, it has endured four years on and many iterations of Android later, possibly signalling that consumers aren’t ready to let go of the cheap microSD card option just yet – or that phone makers are still offering abysmally small internal storage, propagating the need for external storage solutions.

Either way, something’s got to give.

Micro SD Slot for Mobile phones

Monday, May 11, 2015

After Nearly Claiming His Life, Ebola Lurked in a Doctor’s Eye
Before he contracted Ebola, Dr. Ian Crozier had two blue eyes. After he was told he was cured of the disease, his left eye turned green. Credit Emory Eye Center Emory Eye Center
ATLANTA — When Dr. Ian Crozier was released from Emory University Hospital in October after a long, brutal fight with Ebola that nearly ended his life, his medical team thought he was cured. But less than two months later, he was back at the hospital with fading sight, intense pain and soaring pressure in his left eye.
Test results were chilling: The inside of Dr. Crozier’s eye was teeming with Ebola.
His doctors were amazed. They had considered the possibility that the virus had invaded his eye, but they had not really expected to find it. Months had passed since Dr. Crozier became ill while working in an Ebola treatment ward in Sierra Leone as a volunteer for the World Health Organization. By the time he left Emory, his blood was Ebola-free. Although the virusmay persist in semen for months, other body fluids were thought to be clear of it once a patient recovered. Almost nothing was known about the ability of Ebola to lurk inside the eye.
Despite the infection within his eye, Dr. Crozier’s tears and the surface of his eye were virus-free, so he posed no risk to anyone who had casual contact with him.
More than a year after the epidemic in West Africa was recognized, doctors are still learning about the course of the disease and its lingering effects on survivors. Information about the aftermath of Ebola has been limited because past outbreaks were small: no more than a few hundred cases, often with death rates of 50 percent to 80 percent. But now, with at least 10,000 survivors in Guinea, Liberia and Sierra Leone, patterns are emerging.
A Secondary Problem
Dr. Crozier, 44, ruefully calls himself a poster child for “post-Ebola syndrome”: Besides eye trouble, he has had debilitating joint and muscle pain, deep fatigue and hearing loss. Similar problems are being reported in West Africa, but it is not clear how common, severe or persistent they are. There have even been reports of survivors left completely blind or deaf, but these accounts are anecdotal and unconfirmed.
Doctors say the eye problems, because they threaten sight, are the most worrisome part of the syndrome and most urgently need attention. Dr. Crozier’s condition, uveitis — a dangerous inflammation inside the eye — has also been diagnosed in West Africans who survived Ebola.
At the height of the epidemic, health workers were too overwhelmed with the sick to worry much about survivors. But as the outbreak wanes, the World Health Organization has begun to gather information to help those who have not fully recovered, said Dr. Daniel Bausch, a senior consultant to the W.H.O. and an infectious-disease specialist at Tulane University. He added that the reports of eye trouble were of particular concern.
“It’s a major thing we need to study and provide support for,” Dr. Bausch said. But there are hardly any ophthalmologists in West Africa, and only they have the skills and equipment to diagnose conditions like uveitis that affect the inner chambers of the eye.
At ELWA Hospital in Monrovia, Liberia, run by the missionary group SIM, Dr. John Fankhauser, the medical director, said chronic pain, headaches and eye trouble were the most common physical problems among the hundred or so people attending a special clinic for Ebola survivors. Some have such severe pain that they find it hard to walk, he said. About 40 percent have eye pain, inflammation,blurred vision and blind spots in their visual fields. Some have uveitis.
“We’re seeing symptoms in patients who’ve been out of the treatment unit for up to nine months,” Dr. Fankhauser said. “They’re still very severe and impacting their life every day.” These patients will need medical care for months and maybe years, he predicted.
Dr. Fankhauser said he hoped that specialists in ophthalmology, rheumatology and rehabilitation medicine would visit.
Dr. Crozier's eyes were examined again on March 27 by Dr. Yeh at Emory Eye Center in Atlanta. Eye troubles are common among Ebola survivors. Credit Kevin Liles for The New York Times Kevin Liles for The New York Times
“If they see enough patients, they can help us with the trends of what they are seeing, and that may help direct some of our therapy in the future, even after the team’s gone,” he said.
In Sierra Leone, the picture is much the same, according to Dr. John S. Schieffelin, a physician from the Tulane University School of Medicine who volunteered there. He said a strong, well-organized survivor group met regularly in Kenema.
“The main problems they’re telling me about are lots of body and joint pains, chronic headaches and women who stopped having menstrual periods, and for some it’s been several months,” Dr. Schieffelin said. “There’s quite a bit of vision problems.”
He added, “I have met one former patient that does appear to be deaf.”
The hearing loss could result from brain inflammation or very low blood pressure for an extended period, both caused by Ebola, Dr. Schieffelin said.
Alarming Test Results
When Dr. Crozier’s eye trouble began, he and the Emory team suspected that Ebola had weakened his immune system and left him vulnerable to some other virus that had invaded his eye, maybe one that would be treatable with an antiviral drug.
So Dr. Steven Yeh, an ophthalmologist, pierced Dr. Crozier’s eye with a hair-thin needle, drew a few drops of fluid from its inner chamber and sent them to the lab. The results came as a shock.
For Dr. Crozier, it was deeply unsettling to learn that he was still occupied by something that seemed alien and malevolent. “It felt almost personal that the virus could be in my eye without me knowing it,” he said.
Dr. Steven Yeh, an ophthalmologist, examined Dr. Ian Crozier in March, five months after Dr. Crozier's initial recovery from Ebola. Credit Kevin Liles for The New York Times Kevin Liles for The New York Times
Uveitis had been reported in some Ebola survivors from previous outbreaks, and a related virus, Marburg, had been recovered from one patient’s eye. But those cases had seemed uncommon.
A report about Dr. Crozier’s eye condition waspublished on Thursday in The New England Journal of Medicine.
The inside of the eye is mostly shielded from the immune system to prevent inflammation that could damage vision. The barriers are not fully understood, but they include tightly packed cells in minute blood vessels that keep out certain cells and molecules, along with unique biological properties that inhibit the immune system. But this protection, called immune privilege, can sometimes turn the inner eye into a sanctuary for viruses, where they can replicate unchecked. The testes are also immune-privileged, which is why Ebola can persist in semen for months.
Finding Ebola in Dr. Crozier’s eye threw his doctors off balance. Dr. Yeh had worn a protective gown, gloves and a mask but no goggles when he drew the fluid. Doctors wear more protective gear when treating patients known to have Ebola. He could not rule out the possibility that he had been infected, so he slept in the guest room at home and avoided touching his infant son for three weeks, the incubation period of the disease.
Another concern was the examining room where Dr. Yeh had taken the fluid sample. As soon as they got the results, he and several Emory colleagues rushed back there, verified that no one else had used the room, and disinfected every surface.
Additional tests showed that Dr. Crozier’s tears and the outer surface of his eye were Ebola-free, so he posed no danger to others. But his case suggests that doctors performing eye surgery on Ebola survivors could be at risk. It is not known how long the virus can persist within the eye.
The big question was whether the doctors could save Dr. Crozier’s sight. They worried about both eyes, because ailments in one eye can sometimes spread to the other. But there was no antiviral drug proven to work against Ebola, and even if there were, there was no precedent for treating an eye full of the virus.
In addition, the severe inflammation suggested that the barriers that normally protect the eye from the immune system had been breached. So what was damaging Dr. Crozier’s eye? The virus, the inflammation or both? They could not be sure.
The usual treatment for inflammation is steroids. But they can make an infection worse.
Dr. Crozier's left eye regained its blue color following treatment. Read more about what can cause an eye to change color. Credit Kevin Liles for The New York Times Kevin Liles for The New York Times
“What if it unleashed the virus?” Dr. Crozier said. “We were on a tightrope.”
Maybe an experimental antiviral drug would help, the doctors thought.
Weeks of Fear
Though Dr. Crozier was the patient, he was also part of his own medical team, and his focus on the scientific details helped counter his mounting fear that he was going blind.
As he and his physicians struggled to balance treating the inflammation with fighting the infection, his eyesight continued to deteriorate. They tried high doses of a steroid, prednisone. The drug caused mood swings like a teenager’s, ravenous hunger, weight gain, high blood pressure and insomnia. And still his sight worsened. It was like looking through brambles, he said. He reached a point where all he could see was movement when Dr. Yeh waggled his fingers.
He also had significant hearing loss on the same side. “The whole left side of your life is gone,” he said. “It was a very dark and depressing time.”
He spent Christmas in the hospital with his younger brother Mark, who had stayed with him constantly throughout his illness and recovery.
The pressure inside his eye, which had been dangerously elevated, began to drop — too much. The eye became doughy to the touch, as if it were turning to mush.
“The eye felt dead to me,” Dr. Crozier said.
Dr. Crozier with children at an Ebola treatment unit in Sierra Leone in September 2014.
The biggest shock came one morning about 10 days after his symptoms started, when he glanced in the mirror and saw that his eye had actually changed color. His iris, normally bright blue, had turned a vivid green. Rarely, severe viral infections can cause such a color change, and it is usually permanent.
“It was like an assault,” he said. “It was so personal.”
As the days passed with no sign of improvement, Dr. Crozier and the Emory team began to think he had little to lose. Dr. Jay Varkey, an infectious-disease specialist who had handled much of Dr. Crozier’s care, got special permission from the Food and Drug Administration to use an experimental antiviral drug taken in pill form. (The doctors declined to name it, preferring to save that information for future publication in a medical journal.) They were not even sure that the drug would find its way into Dr. Crozier’s eye.
To add to the treatment for inflammation, Dr. Yeh also gave Dr. Crozier a steroid injection above his eyeball that would slowly release the drug into his eye.
Receding Darkness
At first, there seemed to be no effect. But one morning a week or so later, Dr. Crozier realized that if he turned his head this way and that, he could find “portals” and “wormholes” through the obstructions in his eye and could see his brother Mark, who was sitting on the end of his bed.
Gradually, over the next few months, his sight returned. Surprisingly, his eye turned blue again. A video shows him excitedly calling out letters on an eye chart as he works his way down to smaller and smaller type, with his brother and the doctors standing by, laughing.
Was it the antiviral drug? He cannot be sure, but he thinks so.
“I think the cure was Ian’s own immune system,” Dr. Varkey said, explaining that he suspected the treatments had reduced Dr. Crozier’s symptoms and helped preserve his sight long enough for his immune system to kick in and clear out the virus — just as supportive care during the worst phase of his initial illness had kept him alive until his natural defenses could take over.
Dr. Crozier believes information from his case may help prevent blindness in Ebola survivors in West Africa. On April 9, he headed to Liberia with Dr. Yeh and several other Emory physicians to see patients who had recovered from Ebola and examine their eyes.
“Maybe we can change the natural history of the disease for survivors,” Dr. Crozier said. “I want to start that conversation.”

EBOLA the life of survivors

 
Hi-Tech Talk © 2015 - Designed by Templateism.com